We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.
The current 0QSS market cap is 2.2B. The company's latest EPS is -0.01 and P/E is -489.00.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 4.45M | 5.28M | 3.72M | 4.18M | 6.65M |
| Operating Income | -43.62M | -64M | -68.83M | -56.52M | -27.15M |
| Net Income | -38.22M | -62.66M | -73.3M | -53.8M | -228k |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 167.84M | 118.55M | 80.4M | 66.77M | 45.81M |
| Total Liabilities | 22.24M | 32.99M | 53.86M | 43.92M | 22.32M |
| Total Equity | 145.6M | 85.56M | 26.54M | 22.85M | 23.49M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -39.27M | -43.31M | -51.72M | -56.77M | -31.76M |
| Investing | -15.04M | -19.84M | -1.48M | -345k | 38.13M |
| Financing | -818k | 39k | 25.45M | 44.71M | -1.77M |
| Market Cap | 2.2B |
| Price to Earnings Ratio | -489.00 |
| Price to Sales Ratio | 23.29 |
| Price to Cash Ratio | 3.91 |
| Price to Book Ratio | 6.45 |
| Dividend Yield | - |
| Shares Outstanding | 30.99M |
| Average Volume (1 week) | 3 |
| Average Volume (1 Month) | 990 |
| 52 Week Change | 0.0% |
| 52 Week High | 71.025 |
| 52 Week Low | 71.025 |
| Spread (Intraday) | 0.36 (4.88%) |
| Company Name | Phaxiam Therapeutics |
| Address |
60 avenue rockefeller lyon, rhone 69008 |
| Website | https://www.erytech.com |
| Industry | pharmaceutical preparations (2834) |
| Your Recent History | |||||||
Register now to watch these stocks streaming on the ADVFN Monitor.
Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use. Log in to ADVFN
Register Now | |||||||
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
| V: D: 20231001 01:57:16 |
